Lyra Therapeutics (LYRA) Leases (2021 - 2025)
Lyra Therapeutics (LYRA) has disclosed Leases for 5 consecutive years, with $17.6 million as the latest value for Q3 2025.
- On a quarterly basis, Leases fell 15.13% to $17.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $17.6 million, a 15.13% decrease, with the full-year FY2024 number at $19.9 million, down 40.05% from a year prior.
- Leases was $17.6 million for Q3 2025 at Lyra Therapeutics, down from $18.4 million in the prior quarter.
- In the past five years, Leases ranged from a high of $45.6 million in Q1 2024 to a low of $608000.0 in Q3 2022.
- A 5-year average of $11.4 million and a median of $2.2 million in 2022 define the central range for Leases.
- Peak YoY movement for Leases: plummeted 61.9% in 2022, then skyrocketed 2400.05% in 2024.
- Lyra Therapeutics' Leases stood at $1.4 million in 2021, then skyrocketed by 64.06% to $2.2 million in 2022, then surged by 1394.96% to $33.2 million in 2023, then tumbled by 40.05% to $19.9 million in 2024, then fell by 11.79% to $17.6 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's Leases are $17.6 million (Q3 2025), $18.4 million (Q2 2025), and $19.1 million (Q1 2025).